Sanofi, Glaxo start human trials for COVID-19 vaccine
Two of the world’s biggest vaccine makers, began testing their experimental COVID-19 shot in the first patients on Thursday and aim to start late-stage trials before year-end.
Pharmaceutical
-
Elanco’s big job: Making the Bayer deal work
Now that the company has closed its $6.9 billion acquisition of the German conglomerate’s animal-health division, it must now swiftly and carefully integrate the two sprawling companies in the midst of a pandemic.
Read More -
Lilly seeking $23.8M tax break to expand diabetes research, production
In the past seven years, the drugmaker has received tax breaks worth nearly $40 million in exchange for investing more than $500 million at its Indianapolis properties.
Read More -
Lilly teams with British startup to develop autoimmune medicines
In a deal that could eventually be worth close to a billion dollars, Eli Lilly and Co. is teaming with a British biopharmaceutical company in one of the hottest areas in medical research.
Read More -
Lilly teams with Canadian biotech in race to find treatment for COVID-19
The Indianapolis-based drugmaker said it will combine its capability for quickly developing antibodies with AbCellera’s “rapid pandemic response platform,” with the goal of getting a treatment into clinics for human testing within four months.
Read More
Articles
Lilly’s Jardiance pill could get boost to blockbuster status with latest findings
Lilly and partner Boehringer Ingelheim published results from a trial showing the drug cut the risk of cardiovascular hospitalizations or death by 25%, compared to placebo in heart failure patients.
Pfizer executive targets end of year for COVID-19 vaccine
The developers said they have the potential to manufacture up to 100 million vaccine doses by the end of this year and up to 1.3 billion doses by the end of 2021.
With no new law to curb drug costs, Trump tries own changes
President Trump signed four executive orders Friday. One was about importation. The others would direct drugmaker rebates straight to patients, provide insulin and EpiPens at steep discounts, and use lower international prices to pay for some Medicare drugs.
Elanco gets U.S. regulatory approval for $7.6B Bayer acquisition
Shares in Elanco rose 2.8% Wednesday morning after the approval was announced, to $24.13 each.
Novartis unit to build plant for targeted cancer drugs in Indianapolis
A subsidiary of Swiss drug giant Novartis AG announced plans Tuesday to build a targeted radioligand therapy plant at Purdue Research Park near Indianapolis International Airport.
After years of turmoil, biotech testing firm aims to grow again
West Lafayette-based Bioanalytical Systems’ latest executive departure comes amid recent signs of stability, turnaround and growth for a company that just three years ago was on the verge of sinking.
White House wins ruling on health care price disclosure
Health and Human Services Secretary Alex Azar called the decision in federal court in Washington, D.C., “a resounding victory” for President Donald Trump’s efforts to open up the convoluted world of health care pricing.
Court strikes down Trump rule that drugmakers disclose prices
In a major legal setback for President Donald Trump on a high-profile consumer issue, a federal appeals court has ruled that his administration lacks the legal authority to force drug companies to disclose prices in their TV ads.
Researchers say drug improving survival from COVID-19
Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: The cheap, widely available steroid reduced deaths by up to one-third in severely ill hospitalized patients.
Canadian startup wants to be ready with Indy plant when drug hits market
Unlike many pharmaceutical startups, which often contract with outside manufacturers to make their drugs, Point Biopharma is spending $25 million to transform a building in Indianapolis where it hopes to handle its own manufacturing as soon as 2023.
Cancer treatment firm plans to open Indianapolis plant, hire 113
The company is one of many across the globe in a mad rush to develop radioligand therapies for cancer treatment—a field that’s expected to see explosive growth.
Pandemic hobbles drugmakers in recruiting for new studies
The Covid-19 pandemic is hampering research across the pharmaceutical industry, including at Indianapolis-based Eli Lilly and Co.
Coronavirus patients rush to join studies of Gilead drug
Remdesivir is farther along in testing than many other potential therapies, and the current studies could lead to regulatory approval.
FDA authorizes widespread use of unproven drugs to treat coronavirus
The Food and Drug Administration has given emergency approval to a plan to distribute millions of doses of anti-malarial drugs to hospitals across the country, saying it is worth the risk of trying unproven treatments to slow the progression of the disease in seriously ill coronavirus patients.
Karuna Therapeutics, led by former Lilly research leader, opens Carmel office
Karuna Therapeutics Inc., a publicly traded biopharmaceutical company, is developing a potential blockbuster treatment for schizophrenia that got its start at Eli Lilly and Co. decades ago.
Potential coronavirus treatment granted rare disease status
Experts who have studied the so-called “orphan drug” program say the company’s request—and the FDA’s decision to grant it—seem inappropriate given the rapidly expanding threat of the viral outbreak. A financial analyst, though, called Gilead’s request “pretty standard.”
Frustrated health consumers turn to apps, websites to find lowest drug prices
In recent years, a host of online websites and smartphone apps—such as GoodRx, Blink Health and Script Saver—have popped up to help people find the lowest price for prescription medicines. By using them, consumers can save thousands of dollars a year on their prescriptions if they don’t mind shopping around and buying some of their drugs outside their insurance plans.
Lilly reports strong fourth quarter on rising sales of Trulicity, Taltz
The Indianapolis-based drugmaker exceeded analyst expectations for both profit and revenue during the most recent quarter.
Lilly to build $470M manufacturing plant in North Carolina
Eli Lilly and Co. said it considered sites in Indianapolis and Pennsylvania but chose North Carolina for quality of life, cost of operations and geographical diversity.